Liver X receptor activation decreases the severity of experimental autoimmune encephalomyelitis

Journal of Neuroscience Research

Volumn 84, Issue 6, 2006, Pages 1225-1234

  Hindinger, Claudia ^a,b   Hinton, David R ^a   Kirwin, Stefanie J ^a,b   Atkinson, Roscoe D ^a   Burnett, Margaret E ^a   Bergmann, Cornelia C ^a,b   Stohlman, Stephen A ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Central nervous system; Inflammation; Suppression

Indexed keywords

CYTOKINE; HLA ANTIGEN CLASS 2; LIVER X RECEPTOR; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; CYTOKINE RELEASE; DOSE RESPONSE; EXPERIMENTAL MODEL; FLOW CYTOMETRY; HISTOPATHOLOGY; INFLAMMATION; MICROGLIA; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD4; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENES, MHC CLASS II; LIGANDS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; OVALBUMIN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SULFONAMIDES; T-LYMPHOCYTES;

EID: 33750463060     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21038     Document Type: Article

References (45)

1. Apfel R, Benbrook D, Lernhardt E, Ortiz MA, Salbert G, Pfahl M. 1994. A novel orphan receptor specific for a subset of thyroid hormone-responsive elements and its interaction with the retinoid/thyroid hormone receptor subfamily. Mol Cell Biol 14:7025-7035.
2. Barish GD, Evans RM. 2004. PPARs and LXRs: atherosclerosis goes nuclear. Trends Endocrinol Metab 15:158-165.
3. Bergmann CC, Parra B, Hinton DR, Chandran R, Morrison M, Stohlman SA. 2003. Perforin-mediated effector function within the central nervous system requires IFN-gamma-mediated MHC up-regulation. J Immunol 170:3204-3213.
4. Bergmann CC, Parra B, Hinton DR, Ramakrishna C, Dowdell KC, Stohlman SA. 2004. Perform and gamma interferon-mediated control of coronavirus central nervous system infection by CD8 T cells in the absence of CD4 T cells. J Virol 78:1739-1750.
5. Blaschke F, Leppanen O, Takata Y, Caglayan E, Liu J, Fishbein MC, Kappert K, Nakayama KI, Collins AR, Fleck E, Hsueh WA, Law RE, Bruemmer D. 2004. Liver X receptor agonists suppress vascular smooth muscle cell proliferation and inhibit neointima formation in balloon-injured rat carotid arteries. Circ Res 95:e110-e123.
6. Brown A, McFarlin DE, Raine CS. 1982. Chronologic neuropathology of relapsing experimental allergic encephalomyelitis in the mouse. Lab Invest 46:171-185.
7. Cao G, Liang Y, Broderick CL, Oldham BA, Beyer TP, Schmidt RJ, Zhang Y, Stayrook KR, Suen C, Otto KA, Miller AR, Dai J, Foxworthy P, Gao H, Ryan TP, Jiang XC, Burris TP, Eacho PI, Etgen GJ. 2003. Antidiabetic action of a liver X receptor agonist mediated by inhibition of hepatic gluconeogenesis. J Biol Chem 278:1131-1136.
8. Cao G, Liang Y, Jiang XC, Eacho PI. 2004. Liver X receptors as potential therapeutic targets for multiple diseases. Drug News Perspect 17:35-41.
9. Castrillo A, Joseph SB, Marathe C, Mangelsdorf DJ, Tontonoz P. 2003a. Liver X receptor-dependent repression of matrix metalloproteinase-9 expression in macrophages. J Biol Chem 278:10443-10449.
10. Castrillo A, Joseph SB, Vaidya SA, Haberland M, Fogelman AM, Cheng G, Tontonoz P. 2003b. Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol Cell 12:805-816.
11. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, Liao D, Nagy L, Edwards PA, Curtiss LK, Evans RM, Tontonoz P. 2001. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 7:161-171.
12. Chisholm JW, Hong J, Mills SA, Lawn RM. 2003. The LXR ligand T0901317 induces severe lipogenesis in the db/db diabetic mouse. J Lipid Res 44:2039-2048.
13. Collins JL. 2004. Therapeutic opportunities for liver X receptor modulators. Curr Opin Drug Discov Dev 7:692-702.
14. Cua DJ, Hinton DR, Stohlman SA. 1995. Self-antigen-induced Th2 responses in experimental allergic encephalomyelitis (EAE)-resistant mice. Th2-mediated suppression of autoimmune disease. J Immunol 155:4052-4059.
15. Edwards PA, Kast HR, Anisfeld AM. 2002. BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis. J Lipid Res 43:2-12.
16. Feinstein DL, Galea E, Gavrilyuk V, Brosnan CF, Whitacre CC, Dumitrescu-Ozimek L, Landreth GE, Pershadsingh HA, Weinberg G, Heneka MT. 2002. Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann Neurol 51:694-702.
17. Fowler AJ, Sheu MY, Schmuth M, Kao J, Fluhr JW, Rhein L, Collins JL, Willson TM, Mangelsdorf DJ, Elias PM, Feingold KR. 2003. Liver X receptor activators display anti-inflammatory activity in irritant and allergic contact dermatitis models: liver-X-receptor-specific inhibition of inflammation and primary cytokine production. J Invest Dermatol 120:246-255.
18. Glass CK, Rosenfeld MG. 2000. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 14:121-141.
19. Joseph SB, McKilligin E, Pei L, Watson MA, Collins AR, Laffitte BA, Chen M, Noh G, Goodman J, Hagger GN, Tran J, Tippin TK, Wang X, Lusis AJ, Hsueh WA, Law RE, Collins JL, Willson TM, Tontonoz P. 2002. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci U S A 99:7604-7609.
20. Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P. 2003. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 9:213-219.
21. Joseph SB, Bradley MN, Castrillo A, Bruhn KW, Mak PA, Pei L, Hogenesch J, O'Connell RM, Cheng G, Saez E, Miller JF, Tontonoz P. 2004. LXR-dependent gene expression is important for macrophage survival and the innate immune response. Cell 119:299-309.
22. Kainu T, Kononen J, Enmark E, Gustafsson JA, Pelto-Huikko M. 1996. Localization and ontogeny of the orphan receptor OR-1 in the rat brain. J Mol Neurosci 7:29-39.
23. Koldamova RP, Lefterov IM, Staufenbiel M, Wolfe D, Huang S, Glorioso JC, Walter M, Roth MG, Lazo JS. 2005. The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. J Biol Chem 280:4079-4088.
24. Lovett-Racke AE, Hussain RZ, Northrop S, Choy J, Rocchini A, Matthes L, Chavis JA, Diab A, Drew PD, Racke MK. 2004. Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. J Immunol 172:5790-5798.
25. Lund EG, Menke JG, Sparrow CP. 2003. Liver X receptor agonists as potential therapeutic agents for dyslipidemia and atherosclerosis. Arterioscler Thromb Vasc Biol 23:1169-1177.
26. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM. 1995. The nuclear receptor superfamily: the second decade. Cell 83:835-839.
27. Martin R, McFarland HF. 1995. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis. Crit Rev Clin Lab Sci 32:121-182.
28. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. 2001. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19:683-765.
29. lo thymocytes in vivo. Science 250:1720-1723.
30. Neuhaus O, Farina C, Yassouridis A, Wiendl H, Then Bergh F, Dose T, Wekerle H, Hohlfeld R. 2000. Multiple sclerosis: comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc Natl Acad Sci U S A 97:7452-7457.
31. Polak PE, Kalinin S, Dello Russo C, Gavrilyuk V, Sharp A, Peters JM, Richardson J, Willson TM, Weinberg G, Feinstein DL. 2005. Protective effects of a peroxisome proliferator-activated receptor-beta/delta agonist in experimental autoimmune encephalomyelitis. J Neuroimmunol 168:65-75.
32. Repa JJ, Mangelsdorf DJ. 2000. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu Rev Cell Dev Biol 16:459-481.
33. Repa JJ, Mangelsdorf DJ. 2002. The liver X receptor gene team: potential new players in atherosclerosis. Nat Med 8:1243-1248.
34. Rudick RA, Ransohoff RM, Peppler R, VanderBrug Medendorp S, Lehmann P, Alam J. 1996. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann Neurol 40:618-627.
35. Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, Schwendner S, Wang S, Thoolen M, Mangelsdorf DJ, Lustig KD, Shan B. 2000. Role of LXRs in control of lipogenesis. Genes Dev 14:2831-2838.
36. Sedgwick JD, Schwender S, Imrich H, Dorries R, Butcher GW, ter Meulen V. 1991. Isolation and direct characterization of resident microglial cells from the normal and inflamed central nervous system. Proc Natl Acad Sci U S A 88:7438-7442.
37. Steinman L. 1999. Assessment of animal models for MS and demyelinating disease in the design of rational therapy. Neuron 24:511-514.
38. Sun Y, Yao J, Kim TW, Tall AR. 2003. Expression of liver X receptor target genes decreases cellular amyloid beta peptide secretion. J Biol Chem 278:27688-27694.
39. Tontonoz P, Mangelsdorf DJ. 2003. Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol 17:985-993.
40. Tsai MJ, O'Malley BW. 1994. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 63:451-486.
41. Valledor AF. 2005. The innate immune response under the control of the LXR pathway. Immunobiology 210:127-132.
42. Walcher D, Kummel A, Kehrle B, Bach H, Grub M, Durst R, Hombach V, Marx N. 2006. LXR activation reduces proinflammatory cytokine expression in human CD4-positive lymphocytes. Arterioscler Thromb Vasc Biol.
43. Wang L, Schuster GU, Hultenby K, Zhang Q, Andersson S, Gustafsson JA. 2002. Liver X receptors in the central nervous system: from lipid homeostasis to neuronal degeneration. Proc Natl Acad Sci U S A 99:13878-13883.
44. Whitney KD, Watson MA, Collins JL, Benson WG, Stone TM, Numerick MJ, Tippin TK, Wilson JG, Winegar DA, Kliewer SA. 2002. Regulation of cholesterol homeostasis by the liver X receptors in the central nervous system. Mol Endocrinol 16:1378-1385.
45. Zhou J, Marten NW, Bergmann CC, Macklin WB, Hinton DR, Stohlman SA. 2005. Expression of matrix metalloproteinases and their tissue inhibitor during viral encephalitis. J Virol 79:4764-4773.